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Cellular/Molecular
Hypocretin/Orexin Peptides Alter Spike Encoding by
Serotonergic Dorsal Raphe Neurons through Two Distinct
Mechanisms That Increase the Late Afterhyperpolarization
X Masaru Ishibashi,1 X Iryna Gumenchuk,1 X Kenichi Miyazaki,1 X Takafumi Inoue,2 X William N. Ross,1
and X Christopher S. Leonard1
1Department of Physiology, New York Medical College, Valhalla, New York 10595, and 2Department of Life Science and Medical Bioscience, Faculty of
Science and Engineering, Waseda University, Tokyo 162-8480, Japan
Orexins (hypocretins) are neuropeptides that regulate multiple homeostatic processes, including reward and arousal, in part by exciting
serotonergic dorsal raphe neurons, the major source of forebrain serotonin. Here, using mouse brain slices, we found that, instead of
simply depolarizing these neurons, orexin-A altered the spike encoding process by increasing the postspike afterhyperpolarization
(AHP) via two distinct mechanisms. This orexin-enhanced AHP (oeAHP) was mediated by both OX1 and OX2 receptors, required Ca
2
influx, reversed near EK, and decayed with two components, the faster of which resulted from enhanced SK channel activation, whereas
the slower component decayed like a slow AHP (sAHP), but was not blocked by UCL2077, an antagonist of sAHPs in some neurons.
Intracellular phospholipase C inhibition (U73122) blocked the entire oeAHP, but neither component was sensitive to PKC inhibition or
altered PKA signaling, unlike classical sAHPs. The enhanced SK current did not depend on IP3-mediated Ca 2 release but resulted from
A-current inhibition and the resultant spike broadening, which increased Ca 2 influx and Ca 2-induced-Ca 2 release, whereas the
slower component was insensitive to these factors. Functionally, the oeAHP slowed and stabilized orexin-induced firing compared with
firing produced by a virtual orexin conductance lacking the oeAHP. The oeAHP also reduced steady-state firing rate and firing fidelity in
response to stimulation, without affecting the initial rate or fidelity. Collectively, these findings reveal a new orexin action in serotonergic
raphe neurons and suggest that, when orexin is released during arousal and reward, it enhances the spike encoding of phasic over tonic
inputs, such as those related to sensory, motor, and reward events.
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Introduction
Orexin neuropeptides (orexin-A and -B), also known as
hypocretin-1 and -2 (de Lecea et al., 1998; Sakurai et al., 1998), act
via two G-protein-coupled receptors (Sakurai et al., 1998) to in-
fluence multiple homeostatic systems, including those control-
ling reward and arousal (Carter et al., 2009). Indeed, orexins are
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Significance Statement
Orexin peptides are known to excite neurons via slow postsynaptic depolarizations. Here we elucidate a significant new orexin
action that increases and prolongs the postspike afterhyperpolarization (AHP) in 5-HT dorsal raphe neurons and other arousal-
system neurons. Our mechanistic studies establish involvement of two distinct Ca 2-dependent AHP currents dependent on
phospholipase C signaling but independent of IP3 or PKC. Our functional studies establish that this action preserves responsive-
ness to phasic inputs while attenuating responsiveness to tonic inputs. Thus, our findings bring new insight into the actions of an
important neuropeptide and indicate that, in addition to producing excitation, orexins can tune postsynaptic excitability to better
encode the phasic sensory, motor, and reward signals expected during aroused states.
The Journal of Neuroscience, September 28, 2016 • 36(39):10097–10115 • 10097
critical for normal waking and sleep because the loss of orexin
signaling results in the sleep disorder narcolepsy with cataplexy in
animals and humans (Chemelli et al., 1999; Lin et al., 1999; Pey-
ron et al., 2000; Thannickal et al., 2000).
The dorsal raphe (DR) and other monoaminergic nuclei re-
ceive strong orexinergic innervation (Peyron et al., 1998), express
orexin receptors (OxRs) (Trivedi et al., 1998; Marcus et al., 2001)
and are targets through which orexin promotes arousal, sup-
presses sleep (Piper et al., 2000), and prevents cataplexy in nar-
colepsy (Hasegawa et al., 2014). Serotonergic (5-HT) DR
neurons have extensive ascending projections, where 5-HT acts
to regulate mood, reward, feeding, arousal and motor behavior,
and is implicated in the etiology and treatment of psychiatric
disorders, including depression (for review, see Jacobs and For-
nal, 1999; Lowry et al., 2005). Thus, factors influencing output
from these neurons will widely impact CNS function.
5-HT DR neurons fire slowly at tonic rates that vary with
behavioral state, having their highest rates in active waking and
near-zero rates during REM sleep (for review, see Monti, 2011).
Some 5-HT neurons also show a “cluster” or “burst” firing, which
augments 5-HT release (Hajós et al., 2007) and occurs mostly
during waking (Sakai, 2011), when orexin neurons are most ac-
tive (Lee et al., 2005b; Mileykovskiy et al., 2005). 5-HT neurons
also phasically encode sensory/motor events and reward magni-
tude (Ranade and Mainen, 2009; Liu et al., 2014), and the major-
ity of these neurons burst during sucrose reward acquisition (Li et
al., 2016). While orexin neurons fire during reward acquisition
(Hassani et al., 2016), how orexins might influence these firing
patterns of 5-HT DR neurons is unknown. Orexins produce slow
depolarizations throughout the CNS (for review, see Leonard and
Kukkonen, 2014), which result mainly from a noisy cation cur-
rent in DR 5-HT neurons (Brown et al., 2002; Liu et al., 2002;
Kohlmeier et al., 2008). Orexins can also regulate transmitter
release, which is associated with increased GABAergic input (Liu
et al., 2002) and decreased excitatory input (Haj-Dahmane and
Shen, 2005) to 5-HT neurons, suggesting a multifaceted role in
regulating DR output. The firing of DR 5-HT neurons is strongly
regulated by a postspike afterhyperpolarization (AHP) (Aghaja-
nian and Vandermaelen, 1982), mediated by apamin-sensitive,
SK-type, Ca 2-dependent K channels (Freedman and Aghaja-
nian, 1987; Pan et al., 1994; Scuvée-Moreau et al., 2004; Crawford
et al., 2010; Alix et al., 2014) that promotes slow firing (Rouchet et
al., 2008).
Here we show that orexin-A enhances this AHP and that this
orexin-enhanced AHP (oeAHP) results from two distinct mech-
anisms, including both an increased SK current and the induc-
tion of a novel slow-AHP-like current. Moreover, our functional
studies establish that the oeAHP promotes slower and more reg-
ular firing than expected for depolarizing orexin currents, and
that it preserves responsiveness to phasic inputs while attenuat-
ing responsiveness to tonic inputs. Collectively, our findings re-
veal a new modulatory action of orexin that plays a previously
unexpected role in shaping excitability of 5-HT DR neurons to
better encode phasic sensory, motor, and reward signals expected
during aroused states.
Materials and Methods
All procedures complied with National Institutes of Health guidelines
and were approved by New York Medical College Institutional Animal
Care and Use Committee.
Mice and genotyping. Brain slices were prepared from young male and
female C57BL/6N mice (Charles River) and OX1 receptor null, OX2 receptor
null, or double OxR knock-out (DKO) mice (P14-P26). Receptor knock-out
mice were offspring from homozygous null breeders having a mixed C57BL6
and 129/Sv genetic background (kindly provided by Drs. M. Yanagisawa and
R. Chemelli). Use of these mice has been described previously (Willie et al.,
2003; Mieda et al., 2011; Kohlmeier et al., 2013). To confirm the genotype of
each mouse, tail biopsies were obtained during slice preparation and ana-
lyzed by PCR to determine whether each receptor was wild-type or knock-
out. The three primers for OX1 consisted of a common primer (5
CTCTTTCTCCACAGAGCCCAGGACTC 3), a knock-out primer (5
TGAGCGAGTAACAACCCGTCGGATTC 3), and a wild-type primer
(5 gCAAGAATGGGTATGAAGGGAAGGGC 3). The expected product
sizes were 320 bp for the wild-type allele and 500 bp for the knock-out
allele. The three primers for OX2 consisted of a common primer (5 CTG
GTGCAAATCCCCTGCAAA 3), a knock-out primer (5 GGTTTTCC
CAGTCACGACGTTGTA 3), and a wild-type primer (5 AATC
CTTCTAGAGATCCCTCCTAG 3). The expected product sizes were620
bp for wild-type allele and300 bp for the knock-out allele. These two sets of
primers for different OxRs were processed separately, and PCR was per-
formed using 35 cycles of 30 s at 94°C, 30 s at 62°C and 1 min at 72°C,
followed by one cycle at 72°C for 10 min. The result of each PCR was then
fractionated on a 2% agarose gel, and the PCR product was visualized by
ethidium bromide staining.
Brain slice preparation. Mice were decapitated following induction of
deep anesthesia with isofluorane. A block of brain with the target struc-
ture was rapidly removed and incubated and then cut in ice-cold ACSF,
which contained the following (in mM): 124 NaCl, 5 KCl, 1.2 NaH2PO4,
2.7 CaCl2, 1.2 MgSO4, 26 NaHCO3, and 10 dextrose (295–305 mOsm)
and was oxygenated with carbogen (95% O2/5% CO2). Brain slices (250
m) were cut with a Leica vibratome (VT1000S) and were then incu-
bated at 35°C for 15 min in oxygenated ACSF. They were then stored in
continuously oxygenated ACSF at room temperature until use. For re-
cordings, slices were submerged in a chamber that was perfused at 1–2
ml/min with continuously oxygenated ACSF, which was at room tem-
perature (23  2°) for all experiments, except those examining the firing
properties with current clamp and dynamic clamp. For those experi-
ments, slices were superfused with ACSF maintained at 32  1° (see Figs.
9; 10).
Drugs and experimental solutions. Ionotropic receptor antagonists
DNQX (15 M, Sigma), AP5 (50 M, Sigma, Tocris Bioscience), and
SR-95531 (gabazine, 20 M, Sigma) with strychnine (2.5 M, Sigma)
were added to ACSF in all experiments to block synaptic potentials. In
voltage-clamp experiments, TTX (500 nM, Alomone Labs) was added to
block voltage-gated sodium channels. Orexin-A (Peptides International,
3–300 nM) was diluted into ACSF to final concentration from frozen
aliquots just before use. Apamin (100 or 300 nM, Tocris Bioscience),
cyclopiazonic acid (CPA; 10 M, Sigma), phenylephrine (PE; 300 nM to
30 M, Sigma), and prazosin (100 nM, Tocris Bioscience) were dissolved
in ultrapure water at stock concentration and then dissolved in ACSF the
day of the experiment. UCL2077 (10 M, Tocris Bioscience) was dis-
solved in DMSO at 5000 times final concentration. Adenylyl cyclase ac-
tivator forskolin (10 M, Tocris Bioscience) was also dissolved in DMSO
at 2000 times final concentration. Protein kinase C inhibitor peptide
19 –36 (PKCIP; 2 M, Calbiochem) was dissolved in pipette solution at
200 M and then further dissolved to final concentration in pipette solu-
tion on the day of the experiment. PKC inhibitor bisindolylmaleimide I
(Bis I; 1 M, Calbiochem) was dissolved in water at a stock concentration.
PKC activator phorbol 12,13-dibutyrate (PDBu; 1 M, Tocris Biosci-
ence) was dissolved in DMSO at 10 4 times final concentration. Phospho-
lipase C (PLC) inhibitor U73122 (1 M, Tocris Bioscience) and U73343
(1 M, Tocris Bioscience), the inactive analog of U73122, were dissolved
in DMSO at 1000 times final concentration just before use, then diluted
in pipette solution at final concentration. 5-HT (30 M, Tocris Biosci-
ence) was dissolved in ultrapure water at stock concentration and
then dissolved in ACSF at final concentration the day of the experim-
ent. Xestospongin C (XeC; 1 M, Tocris Bioscience) and 2-amino-
ethoxydiphenylborane (2-APB; 50 M, Tocris Bioscience) were dissolved
in DMSO at 1000 and 2000 times final concentration, then diluted in
pipette solution at final concentration, respectively. Ruthenium Red
(RuR, 100 M, Sigma) was dissolved in ultrapure water at 10 mM and then
dissolved in pipette solution at final concentration the day of the exper-
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iment. Voltage-dependent potassium channel blocker 4-aminopyridine
(4-AP; 5 mM, 0.5 mM, Sigma) was directly dissolved in ACSF at final
concentration.
Whole-cell electrophysiological recording, imaging, IP3, and Ca2 un-
caging. Whole-cell recordings (seals  3 G) with simultaneous Ca 2
imaging were obtained from neurons in the DR and other structures
(tuberomammilary nucleus [TMN] or laterodorsal tegmental nucleus
[LDT]) as previously described (Kohlmeier et al., 2008). Briefly, borosili-
cate micropipettes (2– 4 M; catalog #8050, AM Systems) were used and
neurons were visualized for whole-cell recordings at 160  magnification
using visible or near IR light, differential interference contrast optics, and
a Nuvicon tube camera (Dage VE-1000) mounted on a fixed-stage mi-
croscope (Olympus, BX50WI).
Our normal pipette solution contained the following (in mM): 144
K-gluconate, 3 MgCl2, 10 HEPES, 0.3 NaGTP, and 4 Na2ATP (310
mOsm), and Bis-fura-2 (50 M; Invitrogen) was added for calcium-
imaging experiments. For strong and fast calcium buffering, the pipette
solution contained 104 K-gluconate, 3 MgCl2, 10 HEPES, 0.3 NaGTP, 4
Na2ATP, and 10 K4-BAPTA. Biotinylated Alexa-594 (25 M; Invitrogen)
was included in all experiments for cell identification.
To isolate and measure whole-cell Ca 2 currents, the pipette solution
contained the following (in mM): 144 Cs-methanesulfonate, 3 MgCl2, 10
HEPES, 0.3 NaGTP, and 4 Na2ATP, pH adjusted to 7.3 with CsOH, and
the ACSF contained the following (in mM): 124 NMDG, 5 KCl, 1.25
NaH2PO4, 0.25 CaCl2, 3.65 MgSO4, 26 NaHCO3, and 10 dextrose
(295–305 mOsm).
To isolate and measure whole-cell K currents, the normal pipette
solution was used and the ACSF contained the following (in mM): 125.25
NaCl, 5 KCl, 2.7 CoCl2, 1.2 MgCl2, 26 NaHCO3, and 10 dextrose. Cobalt
was added to the ACSF just before each experiment.
Gigaseals were obtained using an Axopatch 200B amplifier (Molecular
Devices) operated in voltage-clamp mode, filtered at 2 or 5 kHz, and
sampled at 20 kHz. Imaging experiments were conducted using a 40
water-immersion objective (0.8 NA) with a MicroMax camera (Roper
Scientific) equipped with an EEV 57 frame-transfer chip (field size 	 160
m/side). Bis-fura-2 was excited at 380 nm using a shuttered 75 W xenon
lamp.
Whole-cell recordings were either conducted in voltage-clamp or “I-
clamp fast” mode, following pipette capacitance compensation; the qual-
ity of the recording was assayed by monitoring holding current, access
resistance and input resistance as determined by the voltage or current
response to a brief, negative going step. These parameters were moni-
tored throughout the recording, and data were discarded from analysis if
access resistance became unstable or changed by 20% between mea-
surements. Recordings were also terminated if cell parameters became
unstable. In most experiments, current and voltage traces were digitized
and command pulses were generated with custom software (TIWB) (In-
oue et al., 1998) run on a Mac OS computer controlling an ITC-18
interface (Instrutech-HEKA) that ensured precise synchronization be-
tween electrophysiological and optical signals.
Images were binned on the chip at 44 and read out through a 1 MHz, 14
bit A/D converter. Images were acquired every 50 ms, a rate fast enough to
monitor changes in [Ca2]i accompanying rapid alterations of the mem-
brane potential. Changes in fluorescence (dF/F) were quantified from the
average pixel values of regions of interest (ROIs) placed on the fluorescence
images. dF was calculated as the difference between the background-
subtracted ROI value for each frame minus the background-subtracted base-
line fluorescence. The background was taken from the value of an ROI
positioned remotely from the filled cell. Baseline fluorescence was the aver-
age ROI values measured over the first few frames of each sequence before
stimulation. dF was then divided by the background-subtracted baseline
fluorescence to compute dF/F. Because Bis-Fura-2 fluorescence resulting
from excitation at 380 nm decreases with calcium binding, dF/F responses
have been inverted for clarity.
Postspike AHPs were evoked by firing single action potentials with
brief (2–3 ms) current pulses adjusted to be suprathreshold, or by a 5
spike protocol consisting of a train of 5 suprathreshold current pulses
(2–3 ms each at 20 Hz). To compare these AHPs, baseline membrane
potential was adjusted to identical values of 
65 or 
70 mV by direct
current injection.
AHP currents were evoked with a 5 pulse protocol consisting of a train
of 5 depolarizing voltage steps to 
5 mV (10 ms duration, 20 Hz) from a
holding potential of 
65 mV and delivered every 30 s. To compute the
AHP current altered by orexin, leak-corrected membrane current evoked
by the 5 pulse protocol was subtracted from the leak-corrected current
evoked by the 5 pulse protocol during orexin action. Because AHP cur-
rents were measured at the holding potential, leak correction was accom-
plished by subtracting the average holding current just before delivering
each 5 pulse protocol.
Isolated Ca 2 and K currents were evoked and recorded using
PCLAMP 8 software (Molecular Devices, RRID: SCR_011323) running
on a PC using a Digidata 1322 (Molecular Devices). Voltage and current
traces were low pass filtered at 2 kHz and sampled at 20 kHz. Leakage
currents and uncompensated capacitive components were subtracted
using a 
P/4 method, implemented in Clampex 8, and both the sub-
tracted and raw current traces were acquired.
Isolated Ca 2 currents were monitored before and after orexin appli-
cation by 30 ms step depolarizations to 
25 mV from a holding potential
of 
65 mV, delivered every 30 s, and confirmed by blockade with extra-
cellular Co 2 (2.7 mM). To measure isolated K currents, three sets of
voltage-clamp experiments were performed before and after orexin ap-
plication. From a holding potential of 
65 mV, delayed rectifier current
was elicited by a series of activation pulses from 
95 mV to 
5 mV in 10
mV increments following a 300 ms inactivation pulse to 
45 mV. To
elicit a transient outward current, the same protocol was repeated with a
150 ms deinactivating prepulse to 
105 mV preceding the activation
steps. The transient currents were then computed by subtracting the first
series of currents from the second series of current. A third series of
pulses to measure the voltage dependence of inactivation was deliv-
ered from a holding potential of 
65 mV. An initial 150 ms inacti-
vating pulse to 
45 mV was followed by a 150 ms prepulse that varied
from 
105 mV to 
35 mV in 10 mV increments and was followed by
a 150 ms test pulse to 
15 mV. The transient current was computed
by subtracting the delayed rectifier current elicited by a test pulse
preceded by a prepulse to 
35 mV. For both Ca 2- and K-current
recordings, uncompensated series resistance was between 4 and 11
M and was electronically corrected by 40%–75%.
Repetitive firing was elicited with constant current steps of 5 s duration
and amplitudes from 50 to 300 pA, delivered once every 20 s. The ability
to fire spikes in response to different frequency trains of stimuli was
assessed with 10 s duration trains of brief (5 ms) current pulses delivered
at 0.5–20 Hz and adjusted in strength (250 pA) to produce a spike by
100% of the pulses delivered at 5 Hz in control conditions.
To simulate the effect of the noisy orexin current on firing, two ap-
proaches were used. In the first approach, a previously recorded inward
orexin current (holding potential of 
65 mV) was scaled and used as the
command current in current-clamp recording experiments. In the sec-
ond approach, a noisy orexin conductance was added by dynamic clamp,
which was implemented using QuB software as modified by Dr. Lorin S.
Milescu (Milescu et al., 2008), running on a PC (ASL, Marquis M517-T)
controlling a National Instruments multifunction PCIe card (NI PCIe-
6251). The virtual orexin conductance was derived from a typical orexin
current recorded at 
65 mV from a DR neuron having an average con-
ductance of 0.5 nS and an estimated reversal potential of 
15 mV. The
normalized conductance fluctuations were computed from the current
fluctuations divided by the driving force and were well fit with a Gaussian
function having a mean of 1.0 and a SD of 0.183. The virtual orexin
current injected by the dynamic clamp was determined by the equation
Iorx 	 Gave  Gfluct  (Vm 
 Vrev), where Gave ranged between 0.5 and 2
nS, Gfluct is the normalized conductance wave, Vm is the membrane
potential, and Vrev is the orexin reversal potential (
15 mV).
To uncage IP3 inside recorded neurons, D-myo-inositol 1,4,5-
trisphosphate, P4(5)-(1-(2-nitrophenyl)ethyl) ester, tris(triethylammo-
nium) salt (NPE-Caged Ins 1,4,5-P3; Invitrogen) was dissolved in
normal patch pipette solution to a final concentration of 100 M.
To uncage Ca 2 inside recorded neurons, 2 mM DMNP-EDTA (1-
(4,5-dimethoxy-2-nitrophenyl)-1,2-diaminoethane-N,N,N,N-tetraac-
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etic acid, ThermoFisher, D6814; DMNP) with 0.75 mM CaCl2 was dis-
solved in normal patch solution containing 100 M Oregon Green
BAPTA 2. Using Patcher’s Power Tools (version 2.19) XOP (http://
www3.mpibpc.mpg.de/groups/neher/index.php?page	aboutppt) for
Igor Pro 6 (Wavemetrics, RRID:SCR_000325), we estimated a resting
free Ca 2 concentration of 70 nM. Both solutions were prepared in low
light, and patching was done using IR illumination. Neurons were filled
for 5 min before experiments began. For caged IP3, photolysis was
accomplished using flashes of 380 nm light provided by our xenon arc
lamp with exposure time controlled by the shutter system. For caged
Ca 2, photolysis was accomplished using a Prizmatix Mic-LED emitting
at 385 nm (15 nm FWHM) with exposures determined by computer-
generated TTL pulses gating the controller. To minimize uncaging
within the pipette, the neuron was positioned so that the pipette was
mostly occluded by the edge of the aperture in the light path. DMNP
uncaging pulses were delivered at intervals of 2 min and were inter-
leaved with three 5 pulse protocols.
Data analyses. Data were analyzed and figures prepared using Igor Pro
6. All reported values of Vm have been corrected by 
15 mV to compen-
sate for liquid junction potentials, which were measured for each patch
solution and ACSF combination (range: 
14.7 to 
16.4 mV). Action
potential and AHP amplitudes were measured from the baseline mem-
brane potential. Rinput was measured in current clamp with 
10 or 
20
pA pulses or in voltage clamp with 
10 mV pulses. AHP duration was
measured as time to 50% recovery (T50). Spike-frequency adaptation
(SFA) was determined from the initial (first interspike interval) and
steady-state firing frequency (last 3–5 intervals) produced by 5 s current
pulses. Curve fitting was done using Igor Pro. Single and double expo-
nentials were fit to average currents to estimate time constants (tau). A
Boltzmann function (1/(1  exp (V1/2 
 Vm/k))) was fit to the average
G/Gmax and I/Imax curves measured for the transient outward current to
determine V1/2 and the slope factor, k. All fit coefficients are reported as
the coefficient  the 95% confidence interval. Other results are reported
as mean  SEM. Groups were compared using two-tailed t tests,
ANOVAs, or repeated-measures ANOVAs (Data Desk 6 and 7, Data
Description). Results from these tests are reported as the value of the t
statistic or the F ratio with corresponding degrees of freedom in paren-
theses. Following a significant ANOVA, group differences were com-
pared using Fisher’s least significant difference post hoc tests. Significance
was set at p  0.05. To minimize variability from possible drifts in exper-
imental conditions (e.g., different lots of orexin), treatment and control
responses were obtained from interleaved recordings.
Immunofluorescence. To identify serotonergic neurons, slices were im-
mersion fixed (4% PFA) overnight and cryoprotected (30% sucrose in
PBS). Slices were then resectioned (40 m) on a freezing microtome, and
free-floating sections were immunolabeled with antibodies against
tryptophan hydroxylase (TpH; Abcam, 3907, RRID:AB_304147; and
Covance PSH-327P, RRID:AB_10063449, sheep polyclonals, 1:400). Se-
rotonergic neurons were identified by immunofluorescence using an
Alexa-488-conjugated secondary antibody (Invitrogen, A11015, donkey
anti-sheep).
Results
Large neurons (long axis  25 m) in the dorsal and ventro-
medial portions of the DR nucleus were chosen for recording
(n 	 292) and had an average input resistance of 670.2  38.9
M (n 	 44), which is comparable with previous measurements
(e.g., Rood et al., 2014).
Orexin enhances the late AHP
Orexin-A (300 nM) application produced membrane depolariza-
tion, a clearly discernible increase in membrane potential noise
and firing. To examine the AHP, we repolarized the neurons
(Fig. 1A, 
Iinj) to baseline with DC current and then compared
the AHP produced by the 5 spike protocol (Fig. 1A, right blue
box) to that evoked before orexin-A (Fig. 1A, left, red box). Su-
perimposing the traces (Fig. 1A, right) revealed that, following
orexin application, the peak of the AHP was larger (control: 6.6 
0.5 mV; orexin: 12.7  1.4 mV, n 	 21; paired t test: t(20) 	 4.76,
p  0.05), later, and slower to recover (control T50: 0.62  0.06 s;
orexin T50: 2.2  0.24 s, n 	 21; paired t test: t(20) 	 
7.16, p 
0.05). Of the 22 DR neurons studied in this way, one did not
show this AHP effect. Thirteen neurons that showed this oeAHP
were recovered after recording, and 12 of 13 were TpH-
immunopositive (Fig. 1B). Moreover, an oeAHP was observed in
all cells for which orexin produced a depolarization. It was acti-
vated over the same orexin dose range (Fig. 1C) and developed
over the same time course (Fig. 1D) as the depolarization.
Previous studies showed that adrenergic -1 receptor activa-
tion increases the AHP in DR neurons (Freedman and Aghajan-
ian, 1987; Pan et al., 1994); and because orexins can release
norepinephrine (Hirota et al., 2001), we tested whether the oe-
AHP might result from indirect activation of -1 receptors. We
confirmed that the -1 agonist PE (300 nM to 30 M) depolarized
and enhanced the AHP in mouse DR neurons (3 M PE, AHP
amplitude: 139.0  17.0% of control; AHP duration: 315.4 
63.9% of control, n 	 5) but found that prasozin (100 nM), which
completely blocked the PE effects, failed to block the oeAHP (n 	
11; Fig. 1E). Nevertheless, PE (3 M) enhancement of the AHP
was sufficient to occlude any further enhancement by orexin-A
(300 nM; AHP amplitude in orexin: 102.1  3.8% of AHP in PE,
paired t test: t(4) 	 0.54, p  0.05; AHP duration in orexin: 94.4 
9.3% of AHP in PE; paired t test: t(4) 	 
1.57, p  0.05, n 	 5;
Figure 1F).
Because there are sex differences in 5-HT DR neurons and
baseline firing rates are higher in male rats (Klink et al., 2002), we
examined whether we could detect a sex difference in the late
AHP or in the oeAHP. The control AHPs evoked with the 5 spike
protocol were not different in either amplitude (male: 7.22 
0.79 mV, n 	 11; female: 5.66  0.75 mV, n 	 7; unpaired t test:
t(16) 	 
1.35, p 	 0.19) or in T50 (male: 0.56  0.06 s, n 	 11;
female: 0.68  0.15 s, n 	 7; unpaired t test: t(16) 	 
0.83, p 	
0.42). Moreover, orexin-A (300 nM) strongly increased the am-
plitude and duration of the late AHP in slices from both sexes,
with a trend toward larger increases in slices from females. Nev-
ertheless, no statistically significant difference between males and
females was found in either the amplitude increase (male:
155.5  19.4%, n 	 11; female: 222.8  39.2%, n 	 7; unpaired
t test: t(16) 	 0.17, p  0.05) or duration increase (male: 385.0 
69.1%, n 	 11; female: 459.0  90.9%, n 	 7; unpaired t test:
t(16) 	 
0.66, p  0.05).
Either OxR alone can mediate the oeAHP in DR neurons
Because mRNA for both OX1 and OX2 is expressed in the DR
(Trivedi et al., 1998; Marcus et al., 2001), and either receptor is
sufficient to produce the orexin-mediated inward current
(Kohlmeier et al., 2013), we tested whether each receptor was
competent to produce the oeAHP using slices from mice lacking
one receptor. Application of 300 nM orexin-A evoked a depolar-
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 (Fig. 2B) mice. More-




23.4%, n 	 5; OX2
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: 345.1  98.6%, n 	 5; OX2

/
: 322.8  63.2%,
n 	 5) was different from those recorded in control DR neurons
(amplitude: 194.2  18.4%, n 	 21; duration: 416.1  49.9%,
n 	 21) in slices from C57BL6 mice (Fig. 2C; Amplitude,
ANOVA: F(2,28) 	 0.76, p  0.05; Duration, ANOVA: F(2,28) 	
0.50, p  0.05). To confirm that these OxRs were, indeed, neces-
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sary, we also recorded DR neurons in slices from DKO mice (n 	
5 from 3 DKO mice). Orexin-A (300 nM) produced neither a
depolarization nor a change in the AHP (Fig. 2D, top traces;
amplitude: 97.9  5.6% of control, n 	 5; duration: 99.66  2.6%
of control, n 	 5), although application of PE still produced an
increase in amplitude and duration of the AHP in these neurons
(Fig. 2D, bottom traces). Thus, both OX1 and OX2 are competent
to mediate the oeAHP in DR neurons.
This suggests that orexin could produce an oeAHP in neurons
normally expressing predominantly OX1 or OX2 receptors. To test
this idea, and to determine whether neurons other than DR neurons
expressed this type of orexin action, we examined the effect of
orexin-A on the late AHP of two other arousal-linked targets: the
TMN, where the orexin-mediated depolarization is primarily medi-
ated by OX2 (Eriksson et al., 2001; Willie et al., 2003); and the LDT,
where the orexin-mediated depolarization is primarily mediated by
OX1 (Kohlmeier et al., 2013). We found orexin-A (300 nM) en-
hanced the AHP duration evoked with the 5 spike protocol in
TMN neurons (control: 0.6  0.18 s; orexin: 1.05  0.11 s, n 	
3 of 3; paired t test: t(2) 	 
3.03, p  0.05; Fig. 2E) and in LDT
neurons (control: 0.56  0.12 s; orexin: 2.06  0.83 s, n 	
7/11; paired t test: t(6) 	 1.14, p  0.05; Fig. 2F ). However,
unlike in the DR, the average amplitude of the late AHP was
not increased in TMN neurons (control: 5.0  0.8 mV; orexin:
5.0  1.0 mV, n 	 3 of 3; paired t test: t(2) 	 
0.04, p  0.05)
or LDT neurons (control: 6.8  1.4 mV; orexin: 9.0  1.8 mV,
n 	 7 of 11; paired t test: t(6) 	 
1.99, p  0.05), suggesting
that different mechanisms may be involved. Nevertheless, this
indicates that the AHP enhancing action of orexin is not re-
stricted to DR neurons and can be observed in neuronal
populations naturally expressing a predominance of either
receptor.
Figure 1. Orexin-A enhances a late AHP in serotonergic DR neurons. A, Orexin-A (Orx A) depolarized DR neurons and greatly enhanced the AHP resulting from 5 spikes delivered at 20 Hz (Control:
red dashed box left; Orexin, Orx A: blue dashed box right, following return of Vm to baseline with direct current, 
Iinj). AHPs are expanded and superimposed on the right. B, Cell recorded in A,
visualized with Alexa-594 (Alexa), was immunopositive for TpH. Scale bar, 30 m. C, Orexin-enhanced AHP (mean  SEM time to 50% recovery, 50% Rec, filled triangles) and orexin-mediated
depolarization (mean  SEM current required to keep Vm at baseline, Iinj, filled circles) versus Orexin-A (Orx A) concentration. D, Average time course of Orx A actions on DR neurons (n 	 7). The
mean  SEM AHP parameters time to AHP peak (Peak), AHP amplitude (Amp), and duration of the AHP to 50% recovery (50% Rec) are shown with changes in input resistance (Rin) and the current
injected to keep membrane potential at baseline (Iinj). E, An average of three 5 spike-evoked AHPs before (Control, red) and after (Orx A, blue) orexin-A (300 nM) in ACSF containing prazosin (100 nM).
F, The 5 spike-evoked AHP before (Control, red), during PE (3 M, green) and during PE  orexin-A (300 nM, PE  Orx A, blue). Scale bars in E apply to F.
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The AHP enhanced by orexin requires
elevation of [Ca2]i
Because the postspike AHP in DR neu-
rons is Ca 2-dependent, and orexin en-
hances somatic Ca 2 transients produced
by long depolarizing pulses in DR neu-
rons (Kohlmeier et al., 2008), we exam-
ined whether the oeAHP resulted from
enhanced spike-evoked Ca 2 transients.
Somatic Ca 2 transients resulting from
single spikes (Fig. 3A, top traces) or the 5
spike protocol (Fig. 3A, bottom traces)
were readily detected and orexin en-
hanced the AHP following both stimuli.
However, orexin did not increase the av-
erage somatic Ca 2 transient produced by
single spikes (orexin: 92.6  3.1% of con-
trol, n 	 7) or by 5 spikes (orexin: 96.7 
10.0% of control, n 	 20; Fig. 3B).
To determine whether elevation of in-
tracellular [Ca 2] was necessary for the
oeAHP, we recorded with a patch solution
containing the fast calcium buffer BAPTA
(10 mM). Under these conditions, the late
AHP following 1 and 5 spikes was unde-
tectable (Fig. 3C), even though recording
conditions remained excellent, as indi-
cated by normal input resistance and ac-
tion potential amplitude (Fig. 3C, inset).
Moreover, despite an intact orexin-
evoked depolarization and large increase
in membrane noise (data not shown), no enhanced AHP follow-
ing 1 or 5 spikes emerged following the application of orexin. This
indicates that the AHP enhanced by orexin requires elevation of
intracellular Ca 2 and did not result from a Ca 2-independent
current that was switched on by OxR activation.
Using a normal internal solution, we next applied ACSF hav-
ing Co 2 substituted for Ca 2 to block voltage-gated Ca 2 chan-
nels and thus determine whether Ca 2 influx was necessary for
the oeAHP. Switching into this ACSF completely blocked the late
AHP following either 1 or 5 spikes (Fig. 3D). Again, despite an
intact orexin-evoked depolarization and a large increase in mem-
brane noise, neither 1 nor 5 spikes elicited an oeAHP following
orexin application (n 	 5), even though recording conditions
remained excellent and action potentials retained their normal
amplitude (Fig. 3D, inset). Moreover, enabling Ca 2 influx by
reintroducing normal Ca 2 ACSF greatly prolonged the late
AHP compared with control, even though the orexin action was
subsiding, as indicated by a recovering inward current. Thus, the
oeAHP requires Ca 2 influx and elevation of intracellular Ca 2.
Orexin enhances an apamin-sensitive K current and a
slower apamin-insensitive current that is insensitive to
UCL2077
We next conducted voltage-clamp recordings to measure the oe-
AHP current (IoeAHP). Following spike blockade with TTX, AHP
currents were evoked using the 5 pulse protocol delivered every
30 s before and after orexin-A application (300 nM; Fig. 4A). As
the noisy inward orexin current developed, a prolonged AHP
current emerged (Fig. 4B; compare top traces). Subtracting these
currents, following leak-correction, yielded the IoeAHP (Fig. 4B,
bottom trace), which decays more slowly than the AHP current in
control condition and underlies the oeAHP observed in current-
clamp experiments.
To estimate the reversal potential of this current, we measured
the instantaneous current-voltage curve resulting from brief voltage
steps timed to occur at the peak of IoeAHP, and delivered both with
and without a preceding 5 pulse protocol (Fig. 4C, inset). These
curves crossed between 
95 and 
100 mV (Fig. 4D; n 	 7) near the
computed EK (
86 mV, dashed line). Shifting EK by 18 mV with
ACSF containing either 2.5 or 10 mM K shifted this estimated re-
versal potential by 
24 mV (n 	 4) and 19 mV (n 	 5), respectively
(data not shown), indicating K channel involvement in IoeAHP.
The Ca 2 dependence and shift in reversal with EK suggest
involvement of Ca 2-activated K channels. Two slow Ca 2-
dependent K currents with different kinetics commonly medi-
ate a medium (ImAHP) and slow AHP (sAHP, IsAHP) in neurons.
Channels mediating ImAHP are mostly blocked by apamin, a se-
lective blocker of channels containing SK1–3 subunits (for re-
view, see Stocker et al., 2004). In contrast, the IsAHP is strongly
inhibited by some neurotransmitters, but the underlying chan-
nels are generally unidentified, often insensitive to channel
blockers and may be different in different neurons (Vogalis et al.,
2003). To test for SK channel involvement, we applied apamin,
which blocks most of the postspike AHP in control condition and
the AHP enhancement produced by PE (Freedman and Aghaja-
nian, 1987; Pan et al., 1994). Following pretreatment with
apamin (100 or 300 nM), our control AHP was blocked by 90%
(100 nM: 88% blocked, n 	 11, paired t test: t(10) 	 11.98, p 
0.05; 300 nM: 91% blocked, n 	 12, paired t test: t(11) 	 6.34, p 
0.05), yet after orexin, IoeAHP amplitude (18.7  1.9 pA, n 	 23)
was only reduced by approximately half (45.0% of control am-
plitude: 41.5  3.4 pA; n 	 11; unpaired t test: t(32) 	 
6.34, p 
0.05; Fig. 4E). This indicates that both an apamin-sensitive SK
Figure 2. Activation of either OxR alone produces the oeAHP. A, B, An average of three 5 spike-evoked AHPs before (Control,
red) and after orexin-A (300 nM; Orx A, blue) in DR neurons recorded in slices from OX1 null mice (A) and OX2 null mice (B). C, The
effects of orexin-A (300 nM; mean percentage of Control  SEM) on the amplitude (Amp) and duration (50% recov) of the 5
spike-evoked AHP. D, An average of three 5 spike-evoked AHPs before (red) and after orexin-A (300 nM; blue) in a DR neuron from
a DKO mouse (top traces). An average of three 5 spike-evoked AHPs before (Control, red) and after PE (10 M; lower traces, PE,
green) in a DR neuron from a DKO mouse. E, F, An average of three 5 spike-evoked AHPs before (red) and after orexin-A (300 nM;
blue) in a TMN neuron (E) and a LDT neuron (F ). All scale bars correspond to those in A.
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current (ISK) and an apamin-insensitive current are involved.
Involvement of two currents was also suggested by the often-
observed biphasic decay kinetics of IoeAHP. To estimate the
time course of each component, we averaged IoeAHP from con-
trol (n 	 7) and apamin pretreated (n 	 7) recordings. In the
control average, the decay was well fit by a medium (tau 	
0.8  0.08 s) and slow exponential (tau 	 6.0  0.02 s; Fig. 4F,
top). In the apamin average, the decay was well fit by a single
slow exponential (tau 	 5.9  0.01 s; Fig. 4F, second trace).
This suggests that the oeAHP results from both an increase in
the medium-duration ISK present before orexin application
and the emergence of a longer-duration apamin-insensitive
current that was absent before orexin application. We con-
firmed the presence of this enhanced ISK by applying apamin
(300 nM) just after emergence of the orexin effect and sub-
tracting the apamin-insensitive component from the initial
orexin-enhanced current, to yield the ISK in orexin. From this,
we then subtracted the SK current before orexin, to yield the
orexin-enhanced SK current (IoeSK). The averaged IoeSK (n 	
6) was well fit with a single exponential having a medium
decay (tau 	 0.71  0.01 s; Fig. 4F, third trace).
The apamin-insensitive part might be
mediated by an IsAHP, which is found in
many types of neurons. The antiepilep-
tic compound UCL2077, which blocks
KCNQ1/2 channels (Soh and Tzingounis,
2010), has recently been found to inhibit the
classical IsAHP in hippocampal pyramidal
neurons (Shah et al., 2006) and in paraven-
tricular thalamic (PVT) neurons, where
orexin inhibits IsAHP (Zhang et al., 2010).
We therefore tested whether UCL2077
blocks the oeAHP current in DR neurons.
Following preapplication of UCL2077 (10
M, 7 min), the oeAHP current was still
biphasic (medium tau 	 1.2  0.03 s; slow
tau 	 6.5  0.08 s; Fig. 4F, fourth trace) and
had an average amplitude of 29.4  6.4 pA
(n 	 4), which was not significantly differ-
ent from that in control ACSF (p  0.05),
indicating that the slow part of the oeAHP is
resistant to UCL2077 and is mediated by
different channels from those mediating the
sAHP in hippocampus and PVT neurons.
PLC antagonism blocks the entire
IoeAHP and the orexin-mediated inward
current, but these currents do not
require PKC activation and are
insensitive to altered cAMP/PKA
signaling
Both OX1 and OX2 can activate PLC, al-
though it has become apparent that
these receptors can also couple to other
second-messenger systems (Kukkonen
and Leonard, 2014). We therefore exam-
ined whether intracellular application of
U73122, an inhibitor of PLC, could in-
hibit the oeAHP. As control, we first eval-
uated the inactive analog U73343 (1 M)
on both the orexin currents and the out-
ward current activated by 5-HT because
the latter current does not depend on PLC
activation (Innis et al., 1988; Williams et al., 1988; Penington et
al., 1993). Under these conditions, orexin and 5-HT produced
their expected actions (n 	 5; Fig. 5A), whereas the active analog
U73122 (n 	 6) blocked both the orexin-mediated inward cur-
rent and the entire IoeAHP,without reducing the 5-HT current
(Fig. 5B). Results from ANOVAs (inward current: F(2,19) 	 6.61,
p  0.05; IoeAHP: F(2,19) 	 5.70, p  0.05) followed by post hoc
testing confirmed that the orexin action was not different from
control in recordings with the inactive analog but was blocked in
recordings with the active analog (post hoc tests, p  0.05; Fig.
5C). In contrast, the active analog did not attenuate the outward
current evoked by 5-HT (unpaired t test, t(9) 	 0.90, p  0.05,
compared with inactive analog; Fig. 5D). Thus, the PLC inhibitor
U73122 selectively blocked both the orexin-mediated inward
current and the IoeAHP.
Neurotransmitter inhibition of the classical IsAHP is mediated
by both cAMP/PKA signaling (Pedarzani and Storm, 1993) and
activation of PLC (Villalobos et al., 2011), with involvement of
PKC in some cases (Malenka et al., 1986; Agopyan and Agopyan,
1991). Indeed, whereas the IsAHP in PVT neurons is inhibited by
both PKA and PKC activation, orexin-mediated inhibition of the
Figure 3. The oeAHP requires Ca 2 influx and the elevation of [Ca 2]i but is not associated with increased somatic Bis-fura-2
transients. A, Ca 2-dependent fluorescence changes from an ROI encompassing the soma (top traces, dF/F) and membrane
potential (bottom traces, mV) were measured concurrently while 1 or 5 spikes were evoked before (red, Control) and after orexin-A
(blue, Orx A, 300 nM) application. B, Summary (mean  SEM) of peak somatic Ca 2 transients (dF/F) produced by 1 and 5 spikes
as a percentage of control following orexin-A treatment. C, Membrane potential following 1 and 5 spikes before (red) and after
(blue) orexin-A (300 nM) recorded with normal ACSF and 10 mM BAPTA in the pipette (average of 3 trials). Boxed inset, Three
superimposed spikes in each condition staggered in time for comparison. Calibration: Inset, 10 ms, 20 mV. D, Membrane potential
following 1 and 5 spikes recorded in control ACSF (black), in ACSF containing no added Ca 2, and 2.7 mM Co 2 (0 Ca 2/2.7 Co 2;
red), following orexin-A (300 nM) in this ACSF (blue) and after reintroduction of control ACSF (green; 5 spikes only). Inset, Three
superimposed spikes in each condition staggered in time for comparison. Calibration: Inset, 10 ms, 20 mV. All calibration, except for
insets, as in A.
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IsAHP was only blocked by PKC inhibitors
(Zhang et al., 2010). We therefore tested
whether the oeAHP might also involve
these signaling pathways. In the first series
of experiments, we tested whether PKCIP
(2 M in the patch solution, dialyzed for
10 min) (Hall et al., 1995; Schubert et
al., 1999) or the PKC inhibitor Bis I (1 M,
brain slices preincubated for 45 min) al-
tered IoeAHP. Before orexin application,
the AHP current produced by the 5 pulse
protocol was 67.4  14.8 pA with the
PKCIP (n 	 4) and 60.4  9.1 pA with Bis
I (n 	 7). Neither of these was different
from the control AHP current (87.4  7.5
pA, n 	 11; ANOVA: F(2,19) 	 2.64, p 
0.05). Application of orexin-A (300 nM)
resulted in an IoeAHP of 36.1  2.5 pA with
the PKCIP (Fig. 5F; n 	 4) and an IoeAHP
of 29.6  5.6 pA with Bis I (Fig. 5G; n 	
7). Neither was different from the IoeAHP
measured in corresponding control ex-
periments (41.5  3.4 pA, n 	 11; Fig.
5E), suggesting that PKC activation is not
required for triggering the oeAHP. In
contrast, the PKC activator PDBu (1 M,
n 	 6) strongly reduced the IoeAHP (4.1 
2.0 pA; Fig. 5H) compared with control
or PKC inhibitor conditions (Fig. 5J;
ANOVA: F(3,24) 	 9.70, p  0.05), sug-
gesting that PKC, when activated, can in-
hibit the expression of IoeAHP.
In the second series of experiments, we
examined involvement of the cAMP/PKA
pathway in regulating the late AHP and
IoeAHP by applying forskolin (10 M; 10
min) before orexin application. The aver-
age amplitude of the late AHP current
produced by the 5 pulse protocol before
forskolin application was 125.5  17.1
pA, and it was unchanged by forskolin ap-
plication (122.1  18.5 pA, paired t test:
t(4) 	 0.90, p  0.05, n 	 5). Following
orexin application with forskolin (300 nM,
n 	 5), the IoeAHP was still observed
(38.6  8.5 pA; Fig. 5I), and it was not
different in amplitude from IoeAHP pro-
duced without forskolin (unpaired t test:
t(14) 	 0.39, p  0.05; Fig. 5E). Thus, un-
like neurotransmitter inhibition of the
classical IsAHP, IoeAHP in DR neurons does
not appear to depend on PKC activation
or the cAMP/PKA system.
Ca 2 stores and Ca 2-induced Ca 2
release (CICR) regulate the SK part of
the oeAHP
Because the oeAHP requires Ca 2 influx and elevation of
[Ca 2]i, and an increase of the apamin-sensitive SK-current con-
tributes to the early part of IoeAHP, we next considered Ca
2-
dependent factors that might be regulated by orexin. First, native
SK2 channels exist in a complex with casein kinase 2 and protein
phosphatase 2A (PP2A) (Bildl et al., 2004), which reciprocally
regulate the Ca 2 sensitivity and kinetics of SK2 currents (Bildl et
al., 2004; Allen et al., 2007). Because SK2 deactivation kinetics are
slowed by PP2A-mediated dephosphorylation, we intracellularly
applied an inhibitor of PP2A (okadaic acid; 25 nM; 12 min) to
determine whether this would shorten the ISK in DR neurons and
perhaps prevent the early, apamin-sensitive part of the oeAHP
Figure 4. The oeAHP current (IoeAHP) reverses near the potassium equilibrium potential (EK) and has a biphasic decay mediated
by a medium duration SK current and a slower apamin-insensitive current. A, Continuous recording of membrane current in
voltage-clamp mode (holding potential 
65 mV) before and during application of orexin-A (Orx A, 300 nM). Intermittent 5 pulse
protocols (delivered 30 s intervals) evoked AHP currents before (left, red dashed box) and after Orx A (right, blue dashed box). B,
Top traces, Leak-corrected currents from A before (red) and after (blue) Orx A (3 traces averaged). Bottom trace (purple), IoeAHP,
computed as the difference between the top traces. C, Membrane current in orexin (magenta) is superimposed on the membrane
current evoked by the 5 pulse protocol (blue) in orexin. Brief (20 ms) voltage pulses (
115 mV to 
55 mV in 10 mV increments,
bottom black trace, inset) were delivered during both traces at a time corresponding to the peak of the oeAHP (bar). The current at
the end of each brief step (top traces, inset) was used to estimate the instantaneous I–V relation. D, Resulting instantaneous
current (mean  SEM, Im)–voltage (Vm) relations for traces without the 5 pulse protocol (
 prepulses, open squares, magenta)
and traces with the 5 pulse protocol ( prepulses, filled squares, blue) cross near the calculated potassium reversal potential (EK;
n 	 7). E, Apamin (100, 300 nM) reduced the amplitude (mean  SEM) of IoeAHP (n 	 23). *p  0.05. F, The average IoeAHP
(purple) under control conditions (n 	 7; top) had a biphasic decay that was well fit with the sum of a medium and slow-decaying
exponential (superimposed white trace). The average IoeAHP in apamin (n 	 7; second trace) decayed with a single slow exponen-
tial (superimposed white trace). The average orexin-enhanced SK current (IoeSK, n 	 5; third trace) was well fit with a medium-
decaying single exponential (superimposed white trace). The average IoeAHP in UCL2077 (n 	 4; fourth trace) also had a biphasic
decay that was well fit with the sum of a medium and slow-decaying exponential (superimposed white trace).
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current. Recordings with okadaic acid in the pipette revealed a
baseline AHP current with a magnitude (76.4  13.5 pA, n 	 7),
similar to that observed with normal pipette solution (87.4  7.5
pA, n 	 11, unpaired t test: t(16) 	 0.77, p  0.05), but with a
duration (T50: 0.42  0.03 s) that was shorter than that with
normal pipette solution (T50: 0.66  0.08 s; unpaired t test: t(16) 	
2.33, p  0.05), consistent with PP2A inhibition and greater SK
phosphorylation. However, IoeAHP recorded under these condi-
tions still showed a biphasic decay with an amplitude (48.5  5.1
pA, n 	 7) that was not different from control (unpaired t test:
t(16) 	 
1.17, p  0.05; Fig. 6A). This indicates that IoeAHP was
resistant to PP2A inhibition and that prolongation of the SK
current by orexin occurred independently of PP2A-mediated
dephosphorylation.
Because IoeAHP depends on PLC, but not on PKC activation,
we next examined whether it might depend on Ca 2 release from
intracellular stores, which could result from PLC-mediated pro-
duction of IP3. We first applied the sarco/endoplasmic reticulum
Figure 5. PLC inhibitor U73122 blocked both the orexin-induced inward current and IoeAHP, although both currents were resistant to PKC inhibitors and forskolin despite being abolished by PDBu.
A1, Continuous membrane current with intermittent 5 pulse protocols (holding potential 	 
65 mV) recorded with U73343 (1 M, inactive analog of U73122) in the pipette before and after
application of Orx A (300 nM; left) or serotonin (5-HT; 30 M; right). A2, IoeAHP (purple) computed from recordings in A1. B1, Membrane current with intermittent 5 pulse protocols (holding
potential 	 
65 mV) recorded with U73122 (1 M, selective PLC inhibitor) in the pipette before and after application of Orx A (300 nM; left) or serotonin (5-HT; 30 M; right). B2, IoeAHP (purple)
computed from recordings in B1 was completely abolished. C, Summary (meanSEM) of currents produced by orexin recorded with either U73343 (n	5) or U73122 (n	6) in the pipette. U73122
strongly attenuated the inward current and IoeAHP. *p  0.05. D, Summary (mean  SEM) of outward current evoked by 5-HT in recordings with U73343 (n 	 5) and U73122 (n 	 6). ns, Not
significant. E–I, Examples of IoeAHP computed for orexin application (300 nM) recorded under different conditions, including control (E), with the PKCIP in the pipette solution (F ), following slice
preincubation with the PKC inhibitor Bis I (G), following application of the PKC activator PDBu (H ), and following preincubation with the adenylyl cyclase activator forskolin (Forsk) (I ). J, Summary
of drug actions on the amplitude of IoeAHP (mean  SEM). **p  0.05, significant comparisons from post hoc Fischer tests following a significant ANOVA, revealing differences between control and
PKC drug groups.
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Ca 2-ATPase (SERCA) inhibitor CPA (10 M, 10 min) to de-
plete intracellular Ca 2 stores in these neurons (Kohlmeier et al.,
2004). In a series of current-clamp experiments, we found that
CPA did not significantly change the amplitude of the SK-
mediated AHP evoked by the 5 spike protocol (Pre-CPA: 7.8 
0.8 mV, CPA: 6.6  0.4 mV, n 	 5, paired t test: t(4) 	 
2.43, p 
0.05), but it did significantly slow its recovery (Pre-CPA T50:
0.7  0.1 s, CPA T50: 1.2  0.1 s, n 	 5, paired t test: t(4) 	 
6.15,
p  0.05). This suggests that SERCA-dependent Ca 2 sequestra-
tion normally contributes to recovery of the SK-mediated AHP.
Following Ca 2-store depletion with CPA, application of
orexin-A (300 nM; Fig. 6B) produced a membrane depolarization
that appeared normal and an oeAHP that achieved the same du-
ration as the oeAHP without CPA (oeAHP with CPA T50: 2.2 
0.3 s, n 	 5; oeAHP no CPA T50: 2.2  0.24 s, n 	 21, unpaired t
test: t(24) 	 0.14, p  0.05). However in CPA, orexin-A applica-
tion did not significantly increase the AHP amplitude (AHP in
CPA: 6.6  0.4 mV; oeAHP in CPA: 8.1  1.2 mV, n 	 5, paired
t test: t(4) 	 0.11, p  0.05). We further tested this in series of
voltage-clamp experiments where we found that the IoeAHP re-
corded in CPA (27.9  3.4 pA, n 	 7; Fig. 6D) was smaller than
that in control conditions but was similar in amplitude to that in
apamin alone and in CPA following preblocking SK channels
with apamin (19.7  2.9 pA, n 	 5). A significant ANOVA
(F(3,42) 	 11.10, p  0.05) followed by post hoc testing confirmed
that the IoeAHP in CPA was significantly smaller than in Control
(p  0.05) but was not different from the IoeAHP recorded in
apamin (p  0.05) or in CPA with apamin (p  0.05). These data
indicate that store release is necessary for the orexin-mediated
enhancement of the apamin-sensitive component, but not for the
longer-lasting apamin-insensitive component of IoeAHP.
We next examined whether store involvement was mediated
by IP3 receptors (IP3Rs) and/or ryanodine receptors (RyRs). In-
tracellular application of the IP3R antagonists XeC (1 M) or
2-APB (50 M) did not reduce IoeAHP (XeC: 47.0  9.2 pA, n 	 6;
2-APB: 52.6  13.7 pA, n 	 6; Fig. 6E,F). In contrast, IoeAHP was
smaller in recordings obtained with the RyR antagonist RuR (100
M) in the patch solution (RuR: 23.3  2.9 pA, n 	 7; Fig. 6E,F),
and this was not further reduced by preblocking SK channels with
apamin (21.9  4.9 pA, n 	 5; Fig. 6F). An ANOVA (F(4,34) 	
4.45, p  0.05) with post hoc testing of these data, following a
log-transform to correct for heterogeneity of variance across re-
cording groups, confirmed that IoeAHP amplitude was not differ-
ent from control (p  0.05) in recordings with XeC or 2-APB but
was smaller than control in recordings with RuR and RuR with
apamin pretreatment (p  0.05). Moreover, when recorded with
Figure 6. The SK portion of the oeAHP requires SERCA-dependent Ca 2 stores and CICR but not IP3. A, An example of IoeAHP recorded with okadaic acid (25 nM) in the pipette solution. AHP
currents were evoked with a 5 pulse protocol before and after orexin-A (300 nM). B, Current-clamp recordings of the AHP evoked by the 5 spike protocol before (black), following SERCA-dependent
Ca 2 store depletion with CPA (red) and during Orx A (300 nM) application in CPA (blue). C, Summary of the effect of CPA treatment on orexin-evoked changes in amplitude (Amp) and duration (50%
recov) of the AHP. Data (mean  SEM) are reported as percentage of the AHP measured in CPA before orexin application (control; dotted line 	 100%). D, Summary of voltage-clamp experiments
following CPA treatment. IoeAHP amplitude (mean  SEM) was measured in CPA and CPA following blockage of SK currents with apamin (CPA w Apa). Dotted lines indicate mean  SEM of the IoeAHP
recorded under control conditions. *p  0.05, significant difference from control. E, Examples of IoeAHP recorded with IP3R inhibitors XeC (1 M) and 2-APB (50 M) and the ryanodine receptor
antagonist RuR (100 M) included in the pipette solution. Calibration bars for left trace apply to the other two traces. F, Summary of IoeAHP amplitude (mean  SEM) for recordings made with XeC,
2-APB, RuR, and RuR with apamin pretreatment. *p  0.05, significant difference compared with Control (mean  SEM, dotted lines) by post hoc tests following an ANOVA. G, Example membrane
currents from a DR neuron (holding potential 	 
65 mV). The neuron was stimulated by IP3 uncaging with full-field UV flashes (500 ms; left traces) or by the 5 pulse protocol (right traces) both
before (red) and after (blue) orexin-A (300 nM). Arrowhead indicates 0 pA. Calibration applies to both pairs of traces. H, Example whole-cell recording from a hippocampal CA1 neuron. Identical IP3
uncaging (UV) evoked an outward current. Calibration in G applies to H. I, Summary of evoked currents by UV uncaging of IP3 in DR neurons before (Control) and after orexin-A application (Orx A)
and in hippocampal CA1 neurons (Hipp). *p  0.05.
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RuR, IoeAHP was not different in amplitude from that recorded in
apamin alone (unpaired t test: t(28) 	 1.23, p  0.05), and the
average decay was well fit by a single exponential (tau 	 2.6 
0.01 s, n 	 7). In addition, apamin pretreatment did not further
reduce IoeAHP recorded with RuR. These data suggest that the
Ca 2 release underlying ISK enhancement requires RyRs but does
not require IP3R activation. This conclusion is tempered by po-
tential off-target actions of these drugs (e.g., see Taylor and
Broad, 1998); so to directly test IP3 involvement, we recorded
from DR neurons with a patch solution containing caged-IP3 and
used full-field UV flashes (500 ms) to release IP3 into the cyto-
plasm. Uncaging IP3 failed to induce a membrane current in DR
neurons either before or after application of orexin (Fig. 6G, left
traces), even though the 5 pulse protocol produced an AHP cur-
rent that was greatly enhanced by orexin in the same neurons
(Fig. 6G, right traces). Similarly, when uncaging was paired with
the 5 pulse protocol (500 ms UV pulse started simultaneously
with the first depolarization), IoeAHP was not altered (paired with
UV amplitude 101.2  6.4% of that without UV, n 	 5, paired t
test: t(4) 	 
0.70, p  0.05). To verify that we were successfully
uncaging IP3, we conducted identical recordings from hip-
pocampal CA1 pyramidal neurons, where
UV flashes produced an outward current
(Fig. 6H), as expected from previous
studies showing perisomatic IP3 uncaging
and ensuing Ca 2 release activates SK
channels (Hong et al., 2007; El-Hassar et
al., 2011). These results are summarized
in Figure 6I. Collectively, these data indi-
cate that enhancement of the SK compo-
nent of the oeAHP involves activation
of ryanodine receptors and Ca 2 release
from intracellular stores, presumably via
CICR, but that activation of IP3Rs are not
necessary or sufficient.
Orexin prolongs the SK component of
IoeAHP via inhibition of A-current and a
resulting increase in local Ca 2 influx
SK channel gating is determined by the
subplasma membrane elevation in Ca 2,
which is not effectively detected by our
bulk cytoplasmic somatic Ca 2 indicator
signals. We therefore reexamined the pos-
sibility that orexin increased spike-evoked
Ca 2 influx. We first measured the action
potential width and found that orexin-A
(300 nM) significantly broadened the
spike (measured at 
25 mV) to 109.0 
2.0% of control (paired t test: t(17) 	 1.74,
p  0.05; Fig. 7A). We also recorded ac-
tion potentials with high intracellular
BAPTA (10 mM) to block possible Ca 2-
dependent K repolarization currents
and found that orexin-A broadened the
spike by 111.5  4.2% of control (paired t
test: t(7) 	 2.34, p  0.05). Similarly, in
voltage-clamp mode, we found that the
poorly clamped Ca 2 action currents
(CACs), evoked by our voltage-steps,
were also augmented by orexin (Fig. 7B).
These orexin effects could result from in-
creasing voltage-gated Ca 2 currents or
reducing spike-repolarization currents. We therefore first exam-
ined the effect of orexin-A on isolated voltage-gated Ca 2 cur-
rents. We monitored the leak-subtracted Ca 2 currents evoked
with 30 ms voltage steps from 
65 mV to 
25 mV. This protocol
was delivered every 30 s before and after orexin-A (300 nM) ap-
plication. This current was relatively stable, although both the
peak inward current and tail current showed a slight run-down
over the course of the recordings. Nevertheless, the current was
not detectably altered by orexin application (Fig. 7C,D).
We next examined whether orexin suppressed voltage-
dependent K currents. We isolated K currents and compared
the effect of orexin-A (300 nM) on both the noninactivating and
inactivating components in the same neurons. Orexin applica-
tion did not change the delayed rectifier currents, but it reduced
the transient outward current by 20% (Fig. 8A–E). Fitting the
normalized activation and inactivation curves with Boltzmann
functions revealed that the corresponding V1/2 and slope factors
(k) were similar before and after orexin (activation before orexin
V1/2: 
30.7  1.9 mV, k: 8.5  1.7; activation after orexin V1/2:

32.2  1.7 mV, k: 8.0  1.5; inactivation before orexin V1/2:

63.7  1.0 mV, k: 
5.6  0.9; inactivation after orexin
Figure 7. Orexin-A broadened action potentials and CACs in DR neurons but did not increase isolated Ca 2 currents. A, Action
potentials were evoked by brief suprathrehold current pulses before (red, Con) and after orexin-A (blue, Orx, 300 nM). Three
superimposed spikes recorded with normal patch solution and ACSF are shown for each condition. B, CACs recorded (voltage steps
from 
65 mV to 
5 mV, 10 ms) with normal internal solution and ACSF containing TTX and synaptic blockers before (red, Con)
and after application of orexin-A (blue, Orx, 300 nM). C, Pharmacologically isolated Ca 2 currents were monitored by stepping Vm
from a holding potential of 
65 mV to 
25 mV for 30 ms every 30 s (Inset) before (red, Con) and orexin-A (blue, Orx, 300 nM).
Superimposed Ca 2 currents are from just before orexin-A application and following 2 min of orexin-A application. D, Summary
of peak Ca 2 current (mean  SEM) evoked as in C and measured before (Con) and after orexin application (Orx). The difference
was not significant (paired t test, p  0.05, n 	 5).
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V1/2: 
64.2  0.7 mV, k: 
6.5  0.6), indicating that the tran-
sient current was reduced without changing voltage dependence
(Fig. 8C–E). Because Co 2-ACSF was used to block voltage-
gated Ca 2 channels in these recordings, these parameters will be
somewhat shifted in the depolarizing direction (Mayer and
Sugiyama, 1988). From additional recordings in normal ACSF
(data not shown), we estimate that the activation curve was pos-
itively shifted by 10 mV, which fits well with previous estimates
(Mayer and Sugiyama, 1988) and indicates this transient outward
current activated below spike threshold. This, and the finding
that the current was largely blocked by 5 mM 4-AP (Fig. 8F),
which produced a characteristic late slowing of inactivation
(Jackson and Bean, 2007), indicates the current is a subthreshold
A-current (Jerng et al., 2004).
In addition to its well-known role in lengthening the interval
between action potentials (Connor and Stevens, 1971), sub-
Figure 8. The enhanced SK component of IoeAHP results from orexin inhibition of A-current but not delayed rectifier current in DR neurons. A, Leak-subtracted (
p/4) delayed rectifier currents
before (left, red) and after (right, blue) application of orexin-A (300 nM; calibrations on right apply to both sets of current). Middle, Voltage protocol and holding potential. Calibration: Middle, 100
ms, 20 mV. B, Summary (meanSEM) of the delayed rectifier current steady-state I–V relations before (open squares, red) and after (filled squares, blue) orexin (n 	6). C, Leak-subtracted (
p/4)
transient outward currents evoked by the A-current activation protocol (middle traces; holding potential and calibration as in A) before (left, red) and after (right, blue) application of orexin-A (300
nM). D, Leak-subtracted (
p/4) transient outward currents evoked by the A-current deinactivation protocol (middle traces; holding potential and calibration as in A) before (left, red) and after (right,
blue) application of orexin-A (300 nM). E, Summary (mean  SEM) of the voltage dependence of activation and inactivation of the transient outward current before (open symbols, red) and after
(filled symbols, blue) orexin application (n 	 6), normalized to the control Imax and Gmax before orexin application. F, The transient outward current was monitored by depolarizing test pulses to

15 mV following a 75 ms hyperpolarizing conditioning pulse to 
105 mV, showing characteristic blocking by 5 mM 4-AP. Three traces before 4-AP application (black) and three traces following
the maximum blockade (red) are superimposed. G, CACs evoked by voltage steps to 
5 mV (10 ms duration) from a holding potential of 
65 mV from before (Con, black), during (4-AP, red)
application of 5 mM 4-AP, and after application of orexin-A (300 nM; Orx, blue). H, SK currents evoked by the 5 pulse protocol (holding potential 	 
65 mV) from before (Con, black) and after
A-current blockade with 5 mM 4-AP (red). I, The average IoeAHP (n 	 8) produced by subsequent application of orexin-A (300 nM) in 5 mM 4-AP. The decay was well fit with a single slow exponential
(white line). J, Outward currents produced by single full-field UV pulses (100 ms) to uncage Ca 2 from DMNP before (red) and after (blue) application of orexin-A (300 nM). The holding current
preceding each trace was subtracted. K, The average IoeAHP (n 	 5) computed from currents evoked by UV pulses (top, uvIoeAHP) and from interleaved 5 pulse protocols (bottom, IoeAHP, 5 pulses).
uvIoeAHP was well fit with a slow single exponential (white line on top trace) while the IoeAHP (5 pulses) was well fit with a double exponential having medium and slow time constants (white line
on bottom trace). Calibration on bottom trace applies to both traces. L, Examples of SK current evoked by a UV pulse (uvISK, UV, 100 ms, left traces) and a 5 pulse protocol (ISK, 5 pulses, right traces)
from before (red) and after (blue) application of orexin-A (300 nM). Holding current preceding each trace was subtracted from each trace. Calibration on right applies to both sets of traces.
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threshold A-currents also function in spike repolarization (Kim
et al., 2005; Yuan et al., 2005), and this inhibition by orexin could
therefore contribute to spike broadening, increased CACs, and
an increase in the SK component of the oeAHP. Consistent with
this idea, orexin (300 nM) produced significant broadening of
action potentials measured with Ca 2 channels blocked by
Co 2-ACSF (spike width at 
25 mV in orexin: 108.8  2.9% of
control, paired t test: t(5) 	 2.57, p  0.05; data not shown). To
more directly test this idea, we applied 4-AP while measuring
CACs and the AHP current. 4-AP (5 mM) enhanced the CACs
(Fig. 8G) and prolonged the SK-mediated AHP in the same cells
(Fig. 8H; Control T50 	 0.48  0.07 s; 4-AP T50 	 0.58  0.09 s,
n 	 8, paired t test: t(7) 	 
2.13, p  0.05). Treatment with 4-AP
also occluded further enhancement of CACs by orexin-A (Fig.
8G) and resulted in an IoeAHP whose amplitude was reduced by
approximately half (18.2  2.7 pA, n 	 8; unpaired t test: t(17) 	

4.99, p  0.05; Fig. 8I) but was not different from that in
apamin (unpaired t test: t(29) 	 0.14, p  0.05). Moreover, the
average IoeAHP in 4-AP decayed with a single component that was
well fit by a single exponential (Fig. 8I; tau 	 4.7  0.03 s) like
that in apamin. Collectively, these findings suggest that the aug-
mented SK component of the oeAHP results from suppression of
an A-current, broader action potentials and enhanced Ca 2 in-
flux, leading to an increase in subplasma membrane Ca 2, which
is further enhanced by CICR. In contrast, the slower-decaying,
apamin-insensitive component of the oeAHP was insensitive to
A-current inhibition, indicating that a different Ca 2-dependent
mechanism must be involved.
Because emerging evidence suggests that store filling can be
modulated by intracellular signaling pathways (Yamasaki-Mann
et al., 2010), additional factors contributing to the augmented ISK
might be that orexin enhances Ca 2 sequestration, leading to
greater store release in response to Ca 2 influx, or that the Ca 2
sensitivity of RyRs or SK channels is increased by orexin signal-
ing. We reasoned that, if these factors are important, identical
Ca 2 transients should trigger enhanced ISK following orexin
application. To bypass the orexin-enhanced CACs, we used full-
field DMNP Ca 2 uncaging (100 –200 ms pulses) before and
after orexin-A (300 nM) application and compared the evoked
outward currents. We found that identical uncaging pulses pro-
duced a reproducible, medium-duration outward current before
orexin that was blocked by apamin (300 nM; data not shown), and
a more slowly decaying current following orexin application that
was reminiscent of IoeAHP (Fig. 8J). The average outward current
produced by Ca 2 uncaging before orexin was 16.9  2.8 pA,
whereas after orexin, the current was 25.0  3.6 pA (n 	 5). We
computed IoeAHP resulting from uncaging pulses and found that
this average current (uvIoeAHP) was reasonably well fit by a single
slow exponential (tau 	 4.70  0.012 s, n 	 5; Fig. 8K, top),
which was similar to the decay of IoeAHP in 4-AP (Fig. 8I). In
contrast, the decay of IoeAHP produced by 5 pulses in these same
neurons was well fit by a double exponential having medium
(tau 	 0.36  0.004 s) and slow (tau 	 5.02  0.012 s) time
constants (Fig. 8K, bottom). Moreover, when we computed the
total ISK evoked by UV after orexin, by applying apamin (300 nM)
after orexin and then subtracting the apamin-insensitive compo-
nent, we found that it was not any longer than ISK before orexin
(T50 before orexin 	 0.34  0.02 s; T50 after orexin 	 0.30 
0.03 s; t(4) 	 1.26, p  0.05; Fig. 8L, left). This differed from the
ISK evoked by the 5 pulse protocol, tested in these same cells,
which increased significantly in duration (T50 before orexin 	
0.33  0.04 s; T50 after orexin 	 0.44  0.05 s; t(4) 	 
2.79, p 
0.05; Fig. 8L, right). It is noteworthy that the prolongation of ISK
by orexin obtained here, using patch solution with DMNP, agrees
well with findings obtained using normal patch solution (ISK T50
before orexin 	 0.35  0.05 s, T50 after orexin 	 0.43  0.07 s;
t(5) 	 3.28, p  0.05; data not shown). Collectively, these findings
suggest that in order for orexin to prolong the ISK and thereby
produce the SK component of the IoeAHP, an enhanced Ca
2
influx is required. Nevertheless, because DMNP alters intracellu-
lar Ca 2 buffering, this conclusion should be considered tenta-
tive. Future experiments using a wider range of Ca 2 release
and buffering conditions would be necessary to fully test this
conclusion.
The firing produced by orexin-A was slower and less variable
than predicted for the depolarizing orexin current
In the final series of experiments, we examined the impact of
orexin and the oeAHP on the firing pattern of DR neurons. Be-
cause these experiments were conducted with the ACSF heated to
32°C, we first confirmed that orexin-A (300 nM) produced an
oeAHP under these conditions. We found that, although the in-
put resistance of DR neurons was lower (393.6  31.4 M; n 	
22; normal ACSF with ionotropic receptor blockers), orexin-A
still significantly increased both the amplitude (control: 7.84 
0.58 mV; orexin: 9.17  0.71 mV, n 	 22; paired t test:
t(21) 	 4.10, p  0.05, paired t test) and duration (control: 0.30 
0.03 s; orexin: 0.55  0.04 s, n 	 22; paired t test: t(21) 	 
5.37,
p  0.05, paired t test) of the late AHP, although, not surprisingly,
these changes were smaller than observed at room temperature.
Twelve cells were recovered and 10 of 12 were TpH.
Increasing the late AHP during the orexin-mediated depolar-
ization might be expected to produce slower firing than the de-
polarization alone. Testing this prediction is complicated by the
lack of blockers specific for just the oeAHP, and by the fact that
orexin inhibits the A-current and produces a large increase in
membrane noise, both of which could increase firing (White et
al., 2000). For the oeAHP to decrease orexin-induced firing, the
orexin-mediated depolarization would have to produce inter-
spike intervals short enough to be influenced by the oeAHP, and
the oeAHP would have to play a more dominant role than
A-current and membrane noise in setting the spike interval. In
the first test, we injected a previously recorded noisy orexin cur-
rent (virtual current) scaled to different average values and com-
pared the resulting firing rate (without an oeAHP; Fig. 9A1) with
the firing rate evoked by an actual orexin current (with the oe-
AHP; Fig. 9A2) produced by application of orexin-A (300 nM).
The magnitude of the actual current was estimated by the injected
current necessary to return membrane potential to baseline dur-
ing the peak effect of orexin-A (Fig. 9A2, arrow). The firing rate,
measured as spikes per second (sps), achieved during orexin-A
application was lower than that produced by the comparable
virtual current (Fig. 9A1), and this firing rate (SD) fell below
the rate-current curve produced by a bracketing range of virtual
currents (Fig. 9A3). In a second test, we used a dynamic clamp to
introduce a virtual orexin conductance (0.5–2 nS) to generate a
noisy, depolarizing orexin current (without the oeAHP). This
orexin current was comparable with that produced by 300 nM
orexin in these and previous DR recordings (Kohlmeier et al.,
2008). We compared the firing evoked by this conductance to the
firing produced by subsequent application of orexin-A (300 nM).
This also showed that the firing rate evoked by the actual
orexin-A current (Fig. 9B2) was lower than that produced by the
comparable virtual conductance (Fig. 9B1), and that this firing
rate fell below the firing rate-average current curve produced by a
range of virtual conductances (Fig. 9B3). These results are sum-
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marized in Figure 9C1 and indicate that the average steady-state
firing rate expected from the virtual inward orexin currents with-
out the oeAHP was significantly higher than the firing rate
evoked by orexin-A with the oeAHP. This was true for cells tested
with both current clamp (virtual: 2.8  0.5 sps vs actual: 1.9  0.3
sps; paired t test: t(4) 	 3.81, p  0.05, n 	 5) and dynamic clamp
(virtual: 1.9  0.5 sps vs actual: 1.2  0.5 sps; paired t test: t(5) 	
3.63, p  0.05, n 	 6).
We next tested the idea that the oeAHP would promote more
regular firing of DR neurons. We compared the SD of the steady-
state firing rate produced by orexin-A with that produced by a
corresponding virtual orexin conductance delivered by dynamic
clamp. Consistent with a role for the oeAHP in promoting more
regular firing, the firing rate variability produced by orexin-A was
lower than that produced by dynamic clamp (Fig. 9C2, vertical
diamonds; virtual SD: 0.73  0.12 vs actual SD: 0.32  0.06,
paired t test: t(5) 	 3.80, p  0.05, n 	 6). The same decrease in
variability was not observed when comparing the firing rate vari-
ability produced by orexin-A with that estimated by current
clamp (virtual SD: 0.36  0.07 vs actual SD 0.29  0.06, paired t
test: t(4) 	 1.07, p  0.05, n 	 5) because the current-clamp
stimulus produced significantly less firing rate variability than
did the virtual conductance (unpaired t test: t(9) 	 2.49, p 
0.05). This lower variability possibly reflects more effective low
pass filtering of the noisy current command by the membrane
because there was not a corresponding fluctuation in conduc-
tance as introduced by the dynamic clamp.
Orexin-A slows steady-state firing and decreases steady-state
firing fidelity
To examine how orexin alters responsiveness of DR neurons
to other excitatory inputs, we examined the repetitive firing
evoked by suprathreshold current steps (5 s, 50 –150 pA) de-
livered from the same baseline membrane potential before and
after orexin application. DR neurons show rapid SFA, with the
initial firing rate decaying to steady-state firing in only a few
interspike intervals. If the oeAHP plays an important role in
regulating spiking, we would expect orexin application to in-
crease SFA by reducing steady-state firing. Indeed, application
of orexin-A (300 nM) increased SFA by increasing the interval
between spikes after the first two spikes and by lowering the
steady-state rate (Fig. 10A). While orexin-A had no significant
effect on the initial rate (Fig. 10B), it significantly lowered
steady-state firing for each current tested (Fig. 10C; repeated-
measures ANOVA: F(1,29) 	 14.81, p  0.05; post hoc tests p 
0.05; n 	 5).
Figure 9. The oeAHP slows the firing rate resulting from the orexin-mediated depolarization. A, Repetitive firing evoked by current clamp (CC) delivery of a previously recorded “noisy” orexin
current (A1) was compared with firing achieved by bath application of orexin-A (A2) in the same neuron (Orx A, 300 nM). Top traces, Instantaneous firing rate (FR, red before; blue during Orx A) in
spikes/s (sps). Middle traces, Vm. Bottom traces, Injected current. Vertical scales are the same in A1 and A2, while the time base differs, as indicated. A2, Filled round symbols represent when the AHP
was tested before (red) and after (blue) orexin (5 pulse protocol). The resulting AHPs are superimposed on the right (boxed inset, red before; blue during Orx A). A2, Arrow indicates application of
hyperpolarizing current to return Vm to baseline. A1, A2, Dashed horizontal line indicates mean firing rate resulting from injected current in A1. A3, Comparison of the mean  SD of steady-state
firing rate (ssFR, mean SD) for this neuron produced by orexin-A (Orx A, filled triangle) and by a range of scaled recorded orexin currents (CC; open horizontal diamonds). B, Repetitive firing evoked
by dynamic clamp (DC) addition of a virtual “noisy” orexin conductance (B1) was compared with the firing rate achieved by bath application of orexin-A (B2). Traces, scaling, and markings as in
A. B3, Comparison of steady-state firing rate for this neuron produced by orexin-A (filled triangle) with a range of virtual orexin conductances (DC; open vertical diamonds). C1, Summary of mean
ssFR produced by orexin-A (actual) and the corresponding CC (open horizontal diamonds; n 	 5) and DC (open vertical diamonds; n 	 6) simulated orexin currents (virtual). *p  0.05, the ssFR
firing produced by orexin-A (Actual) was significantly slower than firing produced by corresponding CC and DC virtual current. C2, Summary of firing rate variability, measured by the SD of
steady-state firing rate produced by orexin-A (Actual) and by the corresponding virtual orexin conductances (Virtual). *p  0.05, the SD produced by orexin-A was significantly lower than that
produced by the corresponding DC virtual current.
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Finally, we examined the effect of orexin on the fidelity with
which DR neurons could fire action potentials in response to
trains of brief suprathreshold current pulses. If the oeAHP plays
an important role in regulating excitability dynamics, we expect
that orexin would produce a decrease in firing fidelity following
spiking onset and the development of the oeAHP. To test this, the
pulse amplitude was adjusted to produce a spike for 100% of
pulses delivered at 5 Hz (100% fidelity; Fig. 10D), which is near
the average rate during active-waking for mouse 5-HT neurons
(Sakai, 2011). As predicted, after the first few spikes, orexin pro-
duced a decrease in firing fidelity (i.e., increased spike failures;
repeated-measures ANOVA: F(1,49) 	 27.32, p  0.05, n 	 5) that
was evident at 5 and 10 Hz (Fig. 10E; post hoc tests, p  0.05,
n 	 5). This had the effect of compressing the steady-state input–
output frequency relationship (Fig. 10F) without changing the
initial input– output relation of 1:1 (Fig. 10F, dotted line).
Of these 10 neurons tested at 32°C, and 10 more tested at
room temperature, which all showed a significant decrease in
steady-state firing, 10 filled neurons were recovered and 8 of 10
were TpH-immunopositive.
Discussion
Here we elucidated a new action of orexin that enhanced the AHP
of 5-HT DR neurons via two distinct mechanisms. We then dem-
onstrated how this action impacts the integrative properties of
these neurons.
Distinct currents underlie the oeAHP
Complete dependence of the oeAHP on Ca 2 influx and eleva-
tion of [Ca 2]i, along with a reversal potential that shifts with EK
in a Nernstian manner, indicate involvement of Ca 2-activated
K channels rather than the electrogenic Na/K ATPase, as
found for some Ca 2-independent sAHPs (e.g., Pulver and Grif-
fith, 2010; Gulledge et al., 2013). Application of apamin revealed
that approximately half of IoeAHP resulted from augmented ISK
(tau 0.5 s), whereas the remainder resulted from induction of a
slow-AHP-like current (tau 5.0 s).
SK augmentation depends on increased spike-evoked Ca 2
influx resulting from A-current inhibition and CICR
SK current likely derives from SK2 and/or SK3 subunits because
mRNA and protein for both localize to the DR (Stocker and
Pedarzani, 2000; Sailer et al., 2004). Because the PP2A antagonist
okadaic acid did not attenuate the SK component of IoeAHP (Fig.
6A), we examined involvement of SK-regulating Ca 2 sources.
Like the -1 adrenoceptor enhancement of SK-AHPs in DR neu-
rons (Pan et al., 1994), the SK component of the oeAHP was
inhibited by Ca 2-store depletion. This -1 action reportedly
involves IP3Rs because IP3 injection transiently (1 min)
lengthened the AHP (Freedman and Aghajanian, 1987). This,
however, did not increase the AHP amplitude, and this effect was
not prolonged by inhibiting IP3 breakdown. In contrast, the
orexin-mediated SK enhancement was inhibited by antagonists
Figure 10. Orexin-A increased spike-frequency adaptation and produced a delayed decrease in firing fidelity. A, Repetitive firing (100 pA, 5 s) before (top trace, Control, red) and during Orx A
action (300 nM; bottom trace, Orx A, blue). Arrow indicates 
65 mV in both traces. Calibration bars apply to both traces. B, Summary of initial firing rate (computed from the first interval; mean 
SEM) versus injected current (I; Control, open circles, red; orexin, filled triangles, blue; n 	 5). C, Summary of steady-state firing (mean  SEM; control, red open circles; orexin, blue filled triangles;
n 	 5). *p  0.05. D, Firing evoked by 10 s duration current pulse-trains (5 ms; 0.5–20 Hz) before (top; Control, red) and after orexin (bottom; Orx A, blue). E, Summary (mean  SEM) of
steady-state firing fidelity (ss Fidelity; percentage pulses that fired a spike in the second half of the train; n 	 5) versus input pulse frequency (Hz) before (red open circles) and during orexin action
(blue filled triangles). *p  0.05, significant difference in orexin. F, Summary (mean  SEM) of steady-state output firing-frequency (n 	 5) versus input pulse-frequency before (Control SS, red
open circles) and during orexin action (Orx A SS, blue filled triangles). *p  0.05, significant difference between control and orexin. Dashed line indicates the initial input– output
relation, which was 1:1.
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of RyRs, rather than IP3Rs, and it was not mimicked by IP3
uncaging, which fits with robust RyR2 and minimal IP3R expres-
sion within DR (Allen Brain Atlas; www.brain-map.org).
Because these findings suggested CICR involvement, we ex-
amined whether orexin enhanced spike-evoked Ca 2 influx and
found that orexin broadened both individual action potentials
and CACs (Fig. 7). Instead of directly augmenting Ca 2 channel
function (Kohlmeier et al., 2008), we found that orexin inhibited
a subthreshold A-current (Fig. 8), which is likely critical because
4-AP (Fig. 7) both prolonged baseline ISK and occluded orexin-
mediated SK enhancement, whereas ISK produced by Ca
2 un-
caging pulses was not enhanced by orexin (Fig. 8). Because Kv4.3
mRNA is differentially expressed in the DR (Serôdio et al., 1998),
it is likely that spike broadening and increased Ca 2 influx result
from orexin-mediated inhibition of A-current, mediated by
Kv4.3 channels. This is a novel orexin action, although orexin can
inhibit (Yang and Ferguson, 2003; Murai and Akaike, 2005) or
increase (Belle et al., 2014) unidentified delayed-rectifier currents
in some other neurons.
Strikingly, -1 receptors also inhibit A-current in DR neurons
(Aghajanian, 1985). This was suggested to increase firing by
shortening the interspike interval, although spike width and
Ca 2 influx were not examined. We confirmed that PE (3 M)
also increased CACs in our slices (M.I. and C.S.L., unpublished
observations), suggesting that A-current inhibition, spike broad-
ening, and increased Ca 2 influx may also contribute to -1
enhancement of SK-AHPs in these neurons. Indeed, PE occluded
the entire oeAHP (Fig. 1E), suggesting that -1 and OxRs share
effectors or signaling components downstream of the receptors
because -1 actions remained intact in the absence of OxRs (Fig.
2D). These findings fit well with the previous demonstration that
orexin and -1 receptor signaling converges in activating inward
current in DR neurons (Brown et al., 2002).
The apamin-insensitive component of IoeAHP differs from the
classical IsAHP
In contrast to SK enhancement, the apamin-insensitive compo-
nent of IoeAHP decayed 10 times slower (tau 5 s; Fig. 4F) and
was absent before orexin application. Moreover, it was insensitive
to store depletion and was not induced or occluded by blocking
A-current, but it was induced by intracellular uncaging of Ca 2,
indicating different Ca 2 requirements. Its slow time course is
reminiscent of the IsAHP (Vogalis et al., 2003) and, like the sAHP
(Lee et al., 2005a), its duration was reduced at elevated temper-
atures. Channels underlying the sAHP have been difficult to
identify, and evidence suggests that different K channels are
involved (for review, see Vogalis et al., 2003; Andrade et al.,
2012). Recently, UCL2077 was shown to block the IsAHP in hip-
pocampal pyramidal neurons (Shah et al., 2006) and the orexin-
inhibited IsAHP in PVT neurons (Zhang et al., 2010). UCL2077
blocks KCNQ1/2 channels, and knock-out evidence suggests in-
volvement of KCNQ2/3 in sAHPs of CA3 and dentate gyrus neu-
rons (Tzingounis and Nicoll, 2008; Tzingounis et al., 2010).
Nevertheless, KCNQ antagonists are not universal blockers of
classical sAHPs (Abel et al., 2004).
Another feature of the classical IsAHP is their suppression by
some neurotransmitters. Monoamines suppress it via cAMP/
PKA signaling (Madison and Nicoll, 1986; Pedarzani and Storm,
1993), and receptors that reduce cAMP, such as adenosine A1 and
GABAB receptors, can modestly increase IsAHP in hippocampal
neurons (Haas and Greene, 1984; Gerber and Gähwiler, 1994).
However, unlike IsAHP in the hippocampus, forskolin did not
alter the oeAHP (Fig. 5I). In the hippocampus, Gq activation by
acetylcholine and glutamate also inhibits IsAHP (Krause et al.,
2002), and IsAHP is suppressed by orexin in PVT neurons via PKC
activation (Zhang et al., 2010). Unlike those sAHPs, PKC inhib-
itors did not alter IoeAHP or the -1 augmentation of the SK-AHP
(Pan et al., 1994) in DR neurons. Nevertheless, PDBu powerfully
suppressed the entire IoeAHP, as reported for -1 actions (Pan et
al., 1994). This suggests that PKC activation is not required for
the oeAHP, but that global activation suppresses orexin and -1-
receptor signaling, perhaps via receptor internalization or desen-
sitization (Chuang et al., 1996; Kelly et al., 2008). Thus, while the
apamin-insensitive component of IoeAHP shares features with
classical sAHPs, insensitivity to forskolin, PKC inhibitors and a
KCNQ blocker indicates it is novel.
Signaling cascades mediating IoeAHP
OxRs are generally thought to activate PLC via Gq/11 (Sakurai
et al., 1998), although their signaling is less well explored in
CNS than expression systems, where OxRs couple to multiple
G-proteins and second messenger systems (for review, see Kuk-
konen and Leonard, 2014). Intracellular application of the PLC
inhibitor U73122, but not its inactive analog U73343, completely
blocked orexin-mediated inward current and the oeAHP, but not
a PLC-independent 5-HT-mediated outward current (Fig. 5A–
D). This fits with expression system evidence for prominent PLC
activation (Holmqvist et al., 2002) and findings from some other
neurons, where PLC inhibitors attenuate orexin actions (Muroya
et al., 2004; Borgland et al., 2006). However, because neither the
inward current nor IoeAHP depended on IP3 or PKC activation,
noncanonical PLC signaling may be involved. While possibilities
abound, one consideration is that U73122 has off-target or indi-
rect effects that influence orexin stimulation of PLA2 (Turunen et
al., 2012) and that arachidonic acid or its metabolites regulate the
inward current and/or the oeAHP. Alternatively, PLC-generated
DAG may be converted to the endocannabinoid 2-AG by DAG-
lipase, and 2-AG or its metabolites are involved. Expressed OxRs
powerfully stimulate 2-AG and arachidonic acid production (Tu-
runen et al., 2012), and inhibition of DAG-lipase blocks OxR-
mediated endocannabinoid inhibition of excitatory input to DR
neurons (Haj-Dahmane and Shen, 2005). It is therefore notewor-
thy that both arachidonic acid and 2-AG can directly inhibit Kv4
channels (Amorós et al., 2010) and broaden action potentials
(Keros and McBain, 1997).
Functional consequences of the oeAHP
The oeAHP enhanced SFA by reducing steady state, but not ini-
tial firing, in response to current steps (Figs. 9; 10), consistent
with functions for slow, Ca 2-dependent AHPs (Faber and Sah,
2003). Dynamic clamp studies revealed that the oeAHP decreases
firing-rate variability, an effect particularly relevant in vivo, where
the coefficient of variation of firing is 10-fold greater (coeffi-
cient of variation 0.5–1.0; waking) (Sakai, 2011) than in our slices
(coefficient of variation 0.06 – 0.1). Increased SFA implies re-
duced excitability for tonic input, as demonstrated by late spike-
failures for pulse-train inputs (5, 10 Hz; Fig. 10D,E) and a
compressed steady-state input– output relation (Fig. 10F). This
reflects the high-pass filter function of SFA (Benda and Herz,
2003), which favors spike encoding of rapidly varying inputs. We
hypothesize that, during active waking, when orexin neuron fir-
ing is highest (Lee et al., 2005b; Mileykovskiy et al., 2005), re-
leased orexin will both depolarize and sharpen the high-pass filter
characteristics of 5-HT neurons. The oeAHP would help limit
and regularize firing in response to tonic input without attenuat-
ing the spike encoding of phasic synaptic inputs related to behav-
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ioral events (Hajós et al., 2007; Ranade and Mainen, 2009; Sakai,
2011; Liu et al., 2014). This may be especially important for pro-
cessing reward signals because orexin neurons increase firing
during anticipation and acquisition of reward (Hassani et al.,
2016) and the firing of most 5-HT DR neurons transition from a
tonic increase to a burst during reward acquisition (Li et al.,
2016). Thus, orexin inputs could provide an arousal/attention
signal that promotes phasic over tonic outflow from raphe neu-
rons, which could affect the relative engagement of postsynaptic
and autoreceptors by released 5-HT (Gartside et al., 2000). Ac-
cordingly, the loss of orexin signaling in narcolepsy would be
expected to impair this signal processing, potentially contribut-
ing to the expression of narcolepsy/cataplexy symptoms (Hase-
gawa et al., 2014) and comorbid symptoms, such as depression,
anxiety, and eating disorders (Fortuyn et al., 2011).
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